Comparison · NCT00486759-sae
Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events. Trial comparisons, record NCT00486759-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00486759-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.567 | 0.518 | 0.615 | wilson | |
| Risk in group 2 | 0.448 | 0.399 | 0.498 | wilson | |
| Risk difference, group 1 minus group 2 | 0.119 | 0.0488 | 0.187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.27 | 1.1 | 1.46 | log | |
| Odds ratio, group 1 over group 2 | 1.61 | 1.22 | 2.14 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Bevacizumab + Rituximab + CHOP than on Placebo + Rituximab + CHOP | 8.41 | 5.34 | 20.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bevacizumab + Rituximab + CHOP | Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone). | 224 | 395 | EG000 |
| Group 2 | Placebo + Rituximab + CHOP | Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone). | 173 | 386 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All adverse events (AE) were reported starting from the first dose up to 92 days after the last dose of study drug. AEs of special interest were reported up to 6 months after the last dose.
Source ClinicalTrials.gov
Trial
- Title
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
- NCT number
- NCT00486759
- Phases
- PHASE3
- Conditions
- B-cell Lymphoma
- Interventions
- Bevacizumab, Rituximab, CHOP, Placebo
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2012-12-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00486759?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00486759-sae